Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using recombinant human protein. The company is headquartered in Burlington, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | -824,964 |
| Operating Margin | 0.00% |
| Return on Equity | -75.40% |
| Return on Assets | -46.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.60 |
| Price-to-Book | 0.55 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.80M |
| Float | $1.79M |
| % Insiders | 0.04% |
| % Institutions | 0.25% |
Volatility is currently contracting
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash
